Are DNA patents bad for medicine?

Health Policy

Volumn 65, Issue 2, 2003, Pages 181-197

  Resnik, David B ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Benefit sharing; Biomedical research; Conflicts of interest; DNA; Exploitation; Medicine; Patenting

Indexed keywords

ARTICLE; ECONOMIC ASPECT; GENETIC PROCEDURES; HEALTH CARE; HUMAN; INSURANCE; MEDICAL PRACTICE; MEDICAL RESEARCH; PATENT;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION; LEGAL APPROACH;

BIOMEDICAL RESEARCH; BIOTECHNOLOGY; COMMERCE; CONFLICT OF INTEREST; DNA; GENETIC RESEARCH; GENOME, HUMAN; HUMANS; INFORMED CONSENT; OWNERSHIP; PATENTS; PROFESSIONAL-PATIENT RELATIONS; SUPREME COURT DECISIONS; UNITED STATES;

EID: 0038351913     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(02)00206-3     Document Type: Article

References (60)

1. Hanson M. Religious voices in biotechnology: the case of gene patenting. Hastings Center Report Special Supplement. 27:(6):1997;1-21.
2. Joint Appeal Against Human and Animal Patenting. Press Conference Text. Washington, DC: Board of Church and Society of the United Methodist Church, May 17, 1995.
3. Enserink M. Patent office may raise the bar on gene claims. Science. 287:2000;1196-1197.
4. Heller M., Eisenberg R. Can patents deter innovation? The anticommons in biomedical research. Science. 280:1998;698-701.
5. Reynolds T. Gene patent race speeds ahead amid controversy, concern. Journal of the National Cancer Institute. 92:(3):2000;184-186.
6. PTO. Revised utility examination guidelines, Federal Register 1999; 64(244):71440-42.
7. Merz J. Disease gene patents: overcoming unethical constraints on clinical laboratory medicine. Clinical Chemistry. 45:(3):1999;324-330.
8. Merz J. Statement Submitted on Gene Patenting. Subcommittee on Courts and Intellectual Property. US House of Representatives Hearing on Gene Patents and Other Genomic Inventions, July 13, 2000.
9. Merz J., Cho M. Disease genes are not patentable: a rebuttal to McGee. Cambridge Quarterly of Healthcare Ethics. 7:1998;425-428.
10. Merz J., et al. Disease gene patenting is bad innovation. Molecular Diagnosis. 2:1997;299-304.
11. Andrews L., Nelkin D. Body Bazaar: The Market for Human Tissue. 2001;Crown Publishers, New York.
12. Kimbrell A. The Human Body Shop. 1997;Gateway Publications, Washington, DC.
13. Venter C., et al. The sequence of the human genome. Science. 291:2001;1304-1351.
14. Pennisi E. The human genome. Science. 291:2001;1177-1180.
15. Kahn P. Coming to terms with genes and risk. Science. 274:1998;496-500.
16. Collins F. Medical and societal consequences of the Human Genome Project. The New England Journal of Medicine. 341:1999;28-37.
17. Collins F., McKusick V. Implications of the Human Genome Project for medical science. Journal of the American Medical Association. 285:2001;540-544.
18. Kleyn P., Vesell E. Genetic variation as a guide to drug development. Science. 281:1998;1820-1821.
19. Diamond vs. Chakrabarty, 447 US 303 (1980).
20. Eisenberg R. Patenting organisms, Encyclopedia of Bioethics. Revised ed. New York: Simon and Schuster, 1995. p. 1911-4.
21. Doll J. The patenting of DNA. Science. 280:1998;689-690.
22. Resnik D. DNA patenting and scientific discovery and innovation: assessing benefits and risks. Science and Engineering Ethics. 7:2001;29-62.
23. US Patent Act. 35 US Code Annotated 101, 112, 161-164 (1984, 1992).
24. Miller A, Davis M. Intellectual Property. 3rd ed. St. Paul, MN: West Group, 2000.
25. Foster F, Shook R. Patents, Copyrights, and Trademarks. 2nd ed. New York: Wiley, 1993.
26. Eisenberg R. Structure and function in gene patenting. Nature Genetics. 15:(2):1997;125-130.
27. Gold R. Body Parts. 1996;Georgetown University Press, Washington, DC.
28. Moore vs. Regents of the University of California. 1990. 793 P.2d 479 (Cal. 1990).
29. Kolata G. Who owns your genes? New York Times. 15 May 2000. p. A1.
30. Greenberg vs. Miami Children's Hospital. Research Institute, Inc. WL 1483266. (N.D.Ill. 2002).
31. Marshall E. Families sue hospital, scientist for control of Canavan gene. Science. 290:2000;1062.
32. Shattuck-Eidens D., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Journal of the American Medical Association. 278:1997;1242-1250.
33. Balter M. Transatlantic war over BRCA1 patent. Science. 292:2001;1818.
34. Foubister V. Gene patents raise concerns for researchers, clinicians. American Medical News. 21 February 2000. p. 1-4.
35. The National Commission. The Belmont Report. Washington, DC: President's Commission, 1978.
36. Tribble J. Gene patents - a pharmaceutical perspective. Cambridge Quarterly of Health Care Ethics. 7:1998;429-432.
37. Woollett G., Hammond O. An industry perspective on the gene patenting debate. Chapman A. Perspectives on Gene Patenting. 1999;43-50 American Association for the Advancement of Science, Washington, DC.
38. Scott R. Testimony before the House Judiciary Subcommittee on Courts and Intellectual Property. 13 July 2000.
39. Biotechnology Industry Organization (BIO). Primer: Genomic and Genetic Research, Patent Protection, and 21st Century Medicine. Washington: BIO, 2000. www.bio.org .
40. Marshall E. Drug firms create public database of genetic mutations. Science. 284:1999;406-407.
41. Nuffield Council on Bioethics. The Ethics of Patenting DNA. London: Nuffield Council, 2002.
42. Genetic Alliance. Statement Submitted on Gene Patenting. Subcommittee on Courts and Intellectual Property. US House of Representatives Hearing on Gene Patents and Other Genomic Inventions. July 13, 2000.
43. Wertheimer A. Exploitation. 1996;Princeton University Press, Princeton, NJ.
44. Dreyfuss R. Collaborative research: conflicts on authorship, ownership, and accountability. Vanderbilt Law Review. 53:2000;1161-1232.
45. Kennedy D. Drug prices: real problem, wrong solution. Science. 292:2001;1797.
46. Bowie N. University-Business Partnerships: an Assessment. 1994;Rowman & Littlefield, Lanham, MD.
47. Brody B. The Ethics of Biomedical Research. 1998;Oxford University Press, New York.
48. Beauchamp T, Childress J. Principles of Biomedical Ethics. 5th ed. Oxford: Oxford University Press, 2002.
49. Levine R. Ethics and the Regulation of Clinical Research. 2nd ed. New Haven, CT: Yale University Press, 1988.
50. National Bioethics Advisory Commission (NBAC). Research Involving Human Biological Materials: Ethical Issues and Policy Guidance. Washington, DC: NBAC, 1998.
51. Emanuel E., Wendler D., Grady C. What makes clinical research ethical? Journal of the American Medical Association. 283:2000;2701-2711.
52. Resnik D. Conflicts of interest in science. Perspectives on Science, 1998;6(4):381-407.
53. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. The New England Journal of Medicine. 342:2000;1539-1544.
54. Korn D. Conflict of interest in biomedical research. Journal of the American Medical Association. 284:2000;2234-2237.
55. Council on Ethical and Judicial Affairs. Current opinions with annotations. Chicago: American Medical Association, 1998.
56. Council on Ethical and Judicial Affairs. Patenting the human genome. Chicago: American Medical Association, 1997.
57. Resnik D. Developing drugs for the developing world. Developing World Bioethics. 1:2001;11-32.
58. Lao M. Unilateral refusals to sell or license intellectual property and the antitrust duty to deal. Cornell Journal of Law and Public Policy. 9:1999;193-219.
59. Melhman M., Botkin J. Access to the Genome. 1998;Georgetown University Press, Washington, DC.
60. Volti R. Society and Technological Change. 3rd ed. New York: St. Martin Press, 1995.